YS110
Based on 1 Customer Validation
YS110 is a humanized anti-CD26 (DPP4) IgG1 monoclonal antibody. YS110 induces CD26 nuclear translocation through the caveolin pathway. YS110 inhibits the proliferation of tumor cell by delaying G2/M cell cycle transition. YS110 inhibits the infection of Middle East respiratory syndrome coronavirus (MERS CoV) by blocking the binding of MERS CoV S1 to CD26. YS110 can be used for researches on cancer or infection such as Malignant Mesothelioma and MERS.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.75%
- No. CAS: 1656248-21-3
- Peso molecular:144.69 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Human IgG1 kappa
Human
|
p38 MAPK |
DPP-4 |
YS110 (0-250 μg/mL, 48 h) inhibits cell proliferation in a concentration dependent manner in NCI-H2452 cells[1].
YS110 (2 μg/mL, 24 h) leads to a significant increase in the proportion of G2/M phase and affects the expression of related proteins in NCI-H2452 cells[1].
YS110 (2 μg/mL, 6-24 h) elevates activating phosphorylation of p38 MAPK and ERK1/2 in NCI-H2452 cells[1].
YS110 (0-20 μg/mL, 48 h) inhibits cell growth of JMN cells in a dose-dependent manner[2].
YS110 (0-4 h) relies on the caveolin pathway to induce CD26 nuclear translocation in JMN cells[2].
YS110 (2 μg/mL, 3 h) significantly inhibits the mRNA and protein levels of POLR2A in JMN cells [2].
YS110 (10 μg/mL, 30 min) effectively inhibits MERS CoV S1-Fc specific binding to CD26 in JKT-hCD26WT cells[3].
YS110 (40 μg/mL, 30 min) significantly reduces MERS CoV infection rate in Huh-7 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:NCI-H2452 cells
-
Concentration:0, 0.1, 2, 10 and 250 μg/mL
-
Incubation Time:48 h
-
Result:Inhibited the cell proliferation of NCI-H2452 cells.
-
Cell Line:NCI-H2452 cells
-
Concentration:2 μg/mL
-
Incubation Time:24 h
-
Result:Significantly increased the proportion of G2/M phase cells with an average increase of 8 %.
-
Cell Line:NCI-H2452 cells
-
Concentration:2 μg/mL
-
Incubation Time:6 and 24 h
-
Result:Significantly increased the level of p21, p-cdc2, p-cdc25C, p-p38 MAPK and p-ERK1/2.
-
Cell Line:JMN cells
-
Concentration:2 μg/mL
-
Incubation Time:3 h
-
Result:Significantly reduced the mRNA level of POLR2A.
-
Cell Line:JMN cells
-
Concentration:2 μg/mL
-
Incubation Time:3 h
-
Result:Significantly reduced the protein level of POLR2A.
YS110 (8 mg/kg or 10 μg, intratumoral injection or i.p., three times per week) significantly inhibits tumor volume and weight in NOG mice bearing JMN or MSTO/clone12 (MSTO/CD26) cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD/Shi-scid, IL-2 receptor gamma null (NOG) mice bearing 1×106 JMN cells[1]
-
Dosage:5 mg/kg or 5 μg
-
Administration:Intratumoral injection of 5 mg/kg; Intraperitoneal injection (i.p.) of 5μg, combinated with Pemetrexed (HY-10820) (100 mg/kg)
-
Result:Significantly inhibited tumor growth, reduced Ki-67 positive cells, and increased necrotic areas.
-
Animal Model:NOD/Shi-scid, IL-2 receptor gamma null (NOG) mice bearing 1×106 JMN cells or MSTO/clone12 (MSTO/CD26) cells[2]
-
Dosage:8 mg/kg or 10 μg
-
Administration:Intratumoral injection of 8 mg/kg; Intraperitoneal injection (i.p.) of 10 μg
-
Result:Significantly inhibited tumor volume and weight, and reduced POLR2A protein levels in tumors.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
ELISA, FACS, Functional assay
-
Immobilized Human DPP4/CD26, His Tag can bind YS110. The EC50 for this effect is 12.91 ng/mL.
Chemical Information
-
No. CAS 1656248-21-3
-
Appearance Liquid
-
Peso molecular 144.69 kDa
-
Color Colorless to light yellow
-
SMILES
N/A
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (266 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
[1]. Hayashi M, et al. A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition. Cancer Cell Int. 2016 Apr 30;16:35. [Content Brief]
[3]. Ohnuma K, et al. Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody. J Virol. 2013 Dec;87(24):13892-9. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
YS110 Related Classifications
HY-P991551 Related Classifications
Powered by Bioz